Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group

Blood

Volumn 99, Issue 3, 2002, Pages 825-833

  Lange, Beverly J ^{a,b,c,d,e,f,g,h,i}   Bostrom, Bruce C ^{a,b,c,d,e,f,g,h,i}   Cherlow, Joel M ^{a,b,c,d,e,f,g,h,i}   Sensel, Martha G ^{a,b,c,d,e,f,g,h,i}   La, Mei K L ^{a,b,c,d,e,f,g,h,i}   Rackoff, Wayne ^{a,b,c,d,e,f,g,h,i}   Heerema, Nyla A ^{a,b,c,d,e,f,g,h,i}   Wimmer, Robert S ^{a,b,c,d,e,f,g,h,i}   Trigg, Michael E ^{a,b,c,d,e,f,g,h,i}   Sather, Harland N ^{a,b,c,d,e,f,g,h,i}  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^c LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^d CHILDREN S ONCOLOGY GROUP   (United States)

^e Ortho Biotech Oncology   (United States)

^f Wayne Hughes Institute   (United States)

^g ALBERT EINSTEIN MEDICAL CENTER   (United States)

^h NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ARTICLE; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL PROTOCOL; CLINICAL TRIAL; FEMALE; HUMAN; INFANT; INTERMETHOD COMPARISON; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; TREATMENT OUTCOME;

EID: 0036464595     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.3.825     Document Type: Article

References (34)

1. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia
2. Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL)
3. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: A report of the CCG-161 study by the Children's Cancer Study Group
4. Prolonged second remissions in childhood acute lymphocytic leukemia: A report from the Children's Cancer Study Group
5. The BFM 76/79 Acute Lymphoblastic Leukemia Therapy Study
6. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features
7. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: A review
8. Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues
9. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: A Children's Cancer Group Study
10. Low numbers of CSF blasts at diagnosis do not predict for the development of CNS leukemia in children with intermediate-risk acute lymphoblastic leukemia: A Children's Cancer Group report
11. Nonparametric estimation from incomplete observations
12. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: Analysis and examples
13. Regression models and life tables
14. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group
15. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy
16. Leukemia after therapy with alkylating agents for childhood cancer
17. Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies
18. U.S. childhood cancer survival, 1973-1987
19. Differences in the presentation of acute lymphoblastic leukemia and non-Hodgkin's lymphoma in black children and white children: A report from the Epidemiology Committee of the Children's Cancer Study Group
20. Cancer incidence, survival, and mortality for children younger than age 15 years
21. Outcome of treatment for childhood cancer in black as compared with white children: The St Jude Children's Research Hospital experience, 1962 through 1992
22. Ethnicity and survival following childhood acute lymphoblastic leukemia (ALL): Follow-up of the Children's Cancer Group (CCG) cohort
23. Gender and treatment outcome in childhood lymphoblastic leukaemia: Report from the MRC UKALL trials
24. Analysis of prognostic factors in acute lymphoblastic leukemia
25. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group Study
26. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: A Children's Cancer Group study
27. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01
28. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01
29. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: A Pediatric Oncology Group Study
30. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL-BFM 86
31. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
32. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital
33. Dexamethasone (DEX) decreases central nervous system (CNS) relapse and improved event-free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL)